Table of Contents
For decades, Parkinson’s disease has been one of medicine’s most difficult challenges. By the time symptoms like tremors and stiffness show up, as much as 80 percent of the brain cells that control movement are already damaged or lost.
The real tragedy is not just the disease, but the years lost during a long, hidden phase when Parkinson’s changes the body without being noticed.
Now, scientists in Sweden and Norway think they have found a way to break that silence. They have discovered a temporary biological marker in the blood that could show signs of Parkinson’s years, or even decades, before symptoms appear.
How Parkinson’s Slowly Develops
Parkinson’s develops slowly, often over 10 to 20 years, while people have no idea it is happening. During this period, cells are already dealing with DNA damage and stress. Still, doctors have not had a way to detect these changes early.
The main question is clear: why hasn’t the medical community created a screening test, even though it is known that Parkinson’s has a long “silent phase”?
The Breakthrough
Researchers at Chalmers University of Technology in Sweden and Oslo University Hospital in Norway used machine learning to study blood samples.
They found a unique pattern of gene activity linked to DNA repair and cell stress. Importantly, this pattern showed up only in people at the very early stage of Parkinson’s and disappeared as the disease progressed.
“This means we’ve found a critical window of opportunity,” says Annikka Polster, Assistant Professor at Chalmers. “The disease leaves a trace in the blood, but only briefly. If we can catch it, then we can intervene before the brain is irreversibly damaged.”
Blood Tests Affordable
Earlier efforts to detect Parkinson’s early used brain scans or spinal fluid tests, which are expensive, invasive, and not practical for large-scale screening.
Blood tests, on the other hand, are affordable, easy to access, and available everywhere.” This paves the way for broad screening tests via blood samples,” Polster explains. “It’s cost-effective and could be deployed widely.”
The Cry for Early Blood Test
Nigeria is facing a growing neurological crisis. With more than 220 million people and longer life expectancy, diseases like Parkinson’s are expected to increase.
However, there is no national screening program for these conditions, and most people are diagnosed only after symptoms become serious.
Public hospitals in Nigeria do not have advanced imaging equipment, so blood-based screening is a practical option.
A simple blood test could be added to routine check-ups and would cost much less than MRI scans or spinal fluid tests.
The Federal Ministry of Health must act now to prioritise screening and early diagnosis of Parkinson’s and other long-term neurological conditions.
Establish national, government-funded screening programs so early detection is available to all, not just those who can pay privately. Make blood-based Parkinson’s tests a standard part of public healthcare. Taking these steps will help Nigerians get diagnosed earlier and access vital treatment sooner.
Neurologists Warn
Local advocates have warned for a long time about the lack of attention to Parkinson’s care. The Adewunmi Desalu Parkinson’s Foundation (ADPF) in Lagos leads the way by providing free physiotherapy and medication to patients who would otherwise not receive help.
“Most of our patients come to us when the disease is already advanced,” says an ADPF coordinator. “If a simple blood test could catch Parkinson’s early, it would transform everything — but only if the government makes it available to ordinary Nigerians.”
At a recent symposium in Lagos, neurologists and caregivers echoed the call. “Nigeria cannot afford to wait until patients are disabled before intervening,” one neurologist warned.
“We require policies that prioritise early detection; otherwise, this breakthrough will remain a headline abroad but never reach our hospitals,” the neurologist added.
Minimal Funding
Globally, the Michael J. Fox Foundation and European research councils are backing early detection. In Nigeria, however, funding for neurological research is minimal. Local universities and teaching hospitals rarely receive grants for Parkinson’s studies, and patient advocacy groups stay small and under-resourced.
Firm Action Needed
These findings demand an immediate response. Patients should not have to wait until severe brain damage before being diagnosed.
It is time for the government to make neurological screening a national priority, fund research, and ensure early detection is accessible everywhere.
Act now—implement national screening, support studies, and open access to early diagnosis. Lives are at stake; decisive action will change the future.
The silent warning signs are here. Nigeria must act now—delay means more suffering. The future of Parkinson’s care depends on what we do next.
